Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL877695 | 0.85 | PBRM1 (0.44) | PBRM1ARCTSDBACE1 | |
| SCHEMBL878093 | 0.85 | PBRM1 (0.44) | PBRM1ARCTSDBACE1 | |
| SCHEMBL877318 | 0.85 | PBRM1 (0.44) | PBRM1ARCTSDBACE1 | |
| SCHEMBL8535309 | 0.81 | PBRM1 (0.35) | PBRM1AROPRM1 | |
| SCHEMBL9932579 | 0.78 | PBRM1 (0.40) | PBRM1AR | |
| SCHEMBL8535428 | 0.78 | PBRM1 (0.40) | PBRM1AR | |
| SCHEMBL9932272 | 0.76 | DRD4 (0.41) | — | |
| SCHEMBL9882137 | 0.75 | BACE1 (0.38) | PBRM1ARPIK3CDPIK3CAPIK3CB | |
| SCHEMBL8534011 | 0.75 | BACE1 (0.38) | PBRM1ARPIK3CDPIK3CAPIK3CB | |
| SCHEMBL8534008 | 0.75 | BACE1 (0.38) | PBRM1ARPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | PBRM1 3853/4885AR 4769/4885OPRM1 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.